{"a":[{"_":"BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test","$":{"href":"/biotech/biontech-genentech-personalized-cancer-vaccine-posts-worse-patient-survival-terminated-ph-2","hreflang":"en"}}]}
Phase 2negativeBioNTech-Genentech personalized cancer vaccineKeytruda-paired personalized mRNA cancer vaccineNegative
AI Analysis
Summary
BioNTech and Genentech's phase 2 personalized cancer vaccine trial was terminated after recording higher mortality in the vaccine group compared to control, contrasting with Merck and Moderna's successful phase 3 results with a similar approach.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Phase 2 trial scrapped; more deaths recorded in vaccine group than control
Importance:8/10
Sentiment:
-0.90
personalized cancer vaccinemRNAphase 2 failuretrial terminationsafety concerns
Related Companies
Read the original article
Published by FierceBiotech on August 28, 2026 1:27 PM